Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia (MAG-PIP)

Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Receiving Treatment for More Than 8 Hours Before Delivery. A Randomized Multicenter Clinical Trial .

There is no evidence that patients receiving magnesium sulfate before birth are required to maintain the drug for 24 hours. Therefore the investigators will have a randomized clinical study in patients with severe preeclampsia who have been treated with impregnation of magnesium sulphate and at least eight hours have received the drug before birth. If the patient agrees and signs the consent is randomized to: 1-receive sulfate for 24 hours postpartum as usual or, 2- not receiving the postpartum magnesium sulfate or other anticonvulsant drugs. This study can be conducted in 12 maternity latin america.

Study Overview

• Status: Completed
• Conditions: Post Partum Severe Preeclampsia
• Intervention / Treatment: Drug: Magnesium Sulfate

Detailed Description

The final treatment known for pre-eclampsia and eclampsia is the termination of pregnancy. However to prevent eclampsia in patients with severe pre-eclampsia has been demonstrated the effectiveness of magnesium sulfate. There are multiple studies that prove the effectiveness of magnesium sulfate to prevent eclampsia in patients with severe disorder of blood pressure during pregnancy. These studies used the drug before birth and continue after birth. Therefore the investigators can not conclude whether the administration just before pregnancy is sufficient to prevent seizure. If the cure or definitive treatment of pre-eclampsia is the interruption, did not seem necessary to justify the administration of drugs anti-eclampsia after birth. Obvious post delivery management with magnesium sulfate arises from the large number of postpartum eclampsia reported in many studies. It is unknown whether administration of magnesium sulfate for a minimum period before delivery, requires even keep the drug post partum.

In addition to magnesium sulfate postpartum, is necessary to maintain urinary catheter to monitoring the removal of magnesium sulfate; is usual to maintain the patient at all or almost all rest by monitoring sulfate and diuresis , this prevents a proper relationship mother and babe and even prevents breastfeeding during that period and is also known increased risk of secondary thromboembolism due to prolonged rest in the postpartum / caesarean section.Thus, maintain magnesium sulfate for 24 hours carries a higher cost, greater vigilance and some risks, without known real effect.

A randomized clinical study conducted by Belfort and colleagues and published in January 2003, where magnesium sulphate compared to nimodipine to prevent eclampsia in women with severe pre-eclampsia, showed interesting outcome. Such research analyzed 819 randomized patients in the nimodipine group and 831 in the magnesium sulfate group. Magnesium sulphate was better than Nimodipine in preventing eclampsia. Interestingly, the greater effectiveness of sulfate appears to prevent all eclampsia postpartum (9 vs 0) and obviously was used before the termination of pregnancy, however no difference compared with nimodipine in eclampsia before birth (12 vs 7).

There are two possible reasons for the non-appearance of postpartum eclampsia: 1- maintain postpartum magnesium sulfate, 2- dose 12-13 grams before birth disruption are sufficient to prevent eclampsia.

The MAGPIE study randomized 1335 postpartum patients (unused sulphate before delivery) using magnesium sulfate postpartum / cesarean (696 women) or placebo postpartum / cesarean (639 women), and found no significant difference in the amount of eclampsia . Thus, the use of magnesium sulfate for first time in the postpartum is not better to use a placebo. If the investigators combine the findings of eclampsia postpartum Belfort study and MAGPIE study is logical to think that the success of the Belfort study in the postpartum is not for the use of magnesium sulfate post delivery and not only due to the termination of pregnancy because there are postpartum eclampsia in the nimodipine group.

If the investigators consider unjustified use of magnesium sulfate postpartum, when maintained at least 8 hours before delivery, the investigators decided to make a non-inferiority randomized study.The investigators assume that using or not using magnesium sulfate during the postpartum prevents similar amount of postpartum eclampsia, if during pregnancy was used (impregnation and at least 8 hours before birth).

For all these reasons the investigators propose the following: A randomized trial is necessary where all those patients who received magnesium sulfate for at least 8 hours before birth (involves impregnation and maintenance 8 hours) will be randomized to two groups of study: 1- Continue magnesium sulfate for 24 hours and 2-not use magnesium sulfate or other anticonvulsant drug post delivery.

This study is planned in 12 maternity latin america

• Study Type: Interventional
• Enrollment (Actual): 1114
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• Dominican Republic
  • Santo Domingo, Dominican Republic
    • Hospital Materno Infantil san Lorezo de las Minas
  • Santo Domingo, Dominican Republic
    • Hospital Universitario Maternidad Nuestra señoa de Alta Gracia
• Ecuador
  • Guayaquil, Ecuador
    • Hospital Teodoro Maldonado De Guayaquil
• El Salvador
  • San Salvador, El Salvador
    • Hospital Primero de Mayo
• Panama
  • Chiriqui, Panama, 507
    • Hospital Jose Domingo de Obaldia
  • Panamá, Panama, 507
    • Complejo Hospitalario Caja de Seguro Social
  • Panamá, Panama, 507
    • Hospital Santo Tomás
• Peru
  • Cajamarca, Peru
    • Hospital Regional de Cojamarca, Perú,
  • Lima, Peru
    • Instituto Materno perinatal, Maternidad de Lima

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 44 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Severe preeclampsia or severe preeclampsia aggregated to chronic hypertension with > 24 weeks of gestation treated with 4-6 grams of magnesium sulfate for impregnation with a minimum of 8 hours continuous of magnesium sulfate before delivery
• The study begins to terminate pregnancy

Exclusion Criteria:

• HELLP syndrome
• Eclampsia
• Renal insufficiency
• Diabetes mellitus
• Disease of collagen
• Heart disease

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Postpartum Magnesium sulfate; The patient will receive magnesium sulfate as usual for 24 hours postpartum	Drug: Magnesium Sulfate; The patient will receive magnesium sulfate for 24 hours postpartum; Other Names: No postpartum treatment
No Intervention: No postpartum treatment; The patient did not receive postpartum magnesium sulfate or other anticonvulsant during 24 hours postpartum

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Eclampsia	Convulsion after delivery in any group (with magnesium sulfate or without magnesium sulfate), during 24 hours postpartum.	24 hours postpartum

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Postpartum hemorrhage	Blood loss > 500 post vaginal delivery or > 800 cc post cesarean section, during 24 hours postpartum	24 hours postpartum
Maternal respiratory distress	clinical respiratory distress,during 24 hours postpartum	24 hours postpartum
Grams of magnesium sulfate before delivery	Hours and grams of magnesium sulfate before delivery	8 to 72 hours with magnesium sulfate before delivery
Severe hypertension postpartum	Diastolic Blood pressure > 110 mmHg and/or systolic blood pressure > 160 mmHg	72 hours postdelivery

Collaborators and Investigators

• Sponsor: Complejo Hospitalario Dr. Arnulfo Arias Madrid
• Investigators: Principal Investigator: Paulino Vigil De Gracia, Complejo Hospitalario Dr. Arnulfo Arias Madrid; Study Chair: Jack Ludmir, MD, School of medicine, Pennsylvania Hospital. University de Pennsylvania. Philadelphia

Publications and helpful links

General Publications

• Belfort MA, Anthony J, Saade GR, Allen JC Jr; Nimodipine Study Group. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med. 2003 Jan 23;348(4):304-11. doi: 10.1056/NEJMoa021180.
• Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith D; Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002 Jun 1;359(9321):1877-90. doi: 10.1016/s0140-6736(02)08778-0.

Study record dates

Study Major Dates

• Study Start: December 1, 2014
• Primary Completion (Actual): December 1, 2015
• Study Completion (Actual): December 1, 2015

Study Registration Dates

• First Submitted: November 24, 2014
• First Submitted That Met QC Criteria: December 1, 2014
• First Posted (Estimate): December 4, 2014

Study Record Updates

• Last Update Posted (Estimate): February 1, 2017
• Last Update Submitted That Met QC Criteria: January 31, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pregnancy Complications; Hypertension, Pregnancy-Induced; Pre-Eclampsia; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anesthetics; Membrane Transport Modulators; Anticonvulsants; Calcium-Regulating Hormones and Agents; Reproductive Control Agents; Calcium Channel Blockers; Tocolytic Agents; Magnesium Sulfate
• Other Study ID Numbers: complejoh